Amylyx Pharmaceuticals logo

Process Engineer, MSAT, Drug Substance

Amylyx Pharmaceuticals

Cambridge, MAHybridPosted 1 day ago$171,000 - $192,000/year
Full TimeSenior LevelManufacturing & CMCPharmaceutical
Original posting ↗

Summary

The Principal Process Engineer, MSAT Drug Substance, will serve as the global process owner and technical subject matter expert for avexitide, a GLP-1 antagonist peptide drug substance, and partner closely with Quality, QC, CMC, and External Manufacturing teams to ensure reliable, compliant, and efficient operational execution. The role is accountable for drug substance technology transfer, process validation, continued process verification, investigations, change control, and process lifecycle management while building collaborative, trust-based relationships across internal and external stakeholders. This role reports to the Director, Manufacturing Sciences and Technology.

Job description

The Opportunity

The Principal Process Engineer, MSAT Drug Substance, will serve as the global process owner and technical subject matter expert for avexitide, a GLP-1 antagonist peptide drug substance, and partner closely with Quality, QC, CMC, and External Manufacturing teams to ensure reliable, compliant, and efficient operational execution. The role is accountable for drug substance technology transfer, process validation, continued process verification, investigations, change control, and process lifecycle management while building collaborative, trust-based relationships across internal and external stakeholders. This role reports to the Director, Manufacturing Sciences and Technology.

Responsibilities

Global Process Ownership and CMC Representation

  • Serve as the global process owner for assigned products ensuring comparability across manufacturing locations.
  • Provide technical authorship and review for regulatory submissions (BLA, NDA, MAA), validation reports, and responses to regulatory agency questions.
  • Represent MSAT on CMC teams as the product drug substance owner and process SME.
  • Assess technical and regulatory impact of potential changes to global process.
  • Author annual product reviews/assessments to satisfy global health authority requirements.
  • Lead process transfers to new manufacturing sites, or larger-scale facilities as required.
  • Partner with technical development to evaluate and implement new process technology as required.

Process Validation

  • Lead drug substance technology transfer activities between clinical, validation, and commercial manufacturing sites.
  • Define critical process parameters (CPPs), critical quality attributes (CQAs), and in-process controls for peptide drug substance unit operations.
  • Develop and execute process validation strategies, including PPQ planning, statistical sampling plans, and acceptance criteria aligned with regulatory guidance.
  • Support new drug substance introductions and commercial launches by ensuring peptide manufacturing processes are validated, scalable, robust, and inspection-ready.

Manufacturing Support

  • Provide technical leadership and day-to-day process engineering support for clinical and commercial drug substance manufacturing at external CDMOs.
  • Serve as the process engineering SME during manufacturing operations, providing onsite support when required.
  • Lead investigations, perform rigorous root cause analysis and develop scientifically sound CAPAs, ensuring alignment with regulatory expectations and industry best practices.
  • Assess and author technical risk assessments and change controls to support manufacturing changes, investigations, and regulatory filings.
  • Ensure strict compliance with cGMPs, global regulatory requirements, and internal quality systems for drug substance manufacturing.
  • Review and provide technical input into master batch records, campaign readiness plans, process descriptions, and manufacturing documentation to ensure process requirements are accurately translated into GMP execution.

Data Analysis & Continued Process Verification

  • Lead continued process verification (CPV) and routine data trending for manufacturing unit operations, in-process controls, and critical process parameters.
  • Develop and maintain data repositories, dashboards, and meaningful KPIs to assess process capability, performance, and trends.
  • Identify early signals of process drift, yield loss, impurity shifts, raw material variability, or scale-dependent performance risks and proactively drive corrective or preventive actions.
  • Prepare and present quarterly CPV summaries and technical assessments for internal management reviews.

Continuous Improvement

  • Identify and execute continuous improvement initiatives focused on process robustness, impurity control, yield, cycle time, capacity, and operational efficiency.
  • Apply Quality by Design (QbD), Design of Experiments (DoE), statistical process control (SPC), and risk-based decision making to optimize drug substance manufacturing processes.
  • Collaborate with CDMOs to implement best practices, new technologies, or process enhancements where appropriate.

Required Qualifications

  • Bachelor's degree in chemical engineering or a related field with 10+ years of relevant experience, or Master's degree with 8+ years of relevant experience.
  • Experience with peptide or biologic drug substance late-phase/commercial manufacturing is required including relevant downstream operations such as chromatography purification, ultrafiltration or diafiltration, and lyophilization.
  • Experience with liquid phase, hybrid, tag-assisted synthesis, or green chemistry peptide manufacturing is a plus.
  • Comprehensive understanding of cGMP principles and regulatory requirements, including process, equipment, and facility validation.
  • Familiarity with modeling and optimization tools (e.g., MATLAB, JMP) is a plus.
  • Detail-oriented with strong problem-solving skills and ability to identify subtle trends in data.
  • Excellent communication and teamwork skills.
  • Demonstrated ability to lead technical discussions with external partners, influence cross-functional decisions without direct authority, and communicate complex process risks clearly to technical and non-technical stakeholders.
  • Ability to travel to domestic and international CMOs up to 20%.

Work Location and Conditions

Amylyx supports remote work opportunities within the United States. However, due to business considerations candidates must be able to attend meetings at the office in Cambridge, MA on a regular basis. Preference will be given to candidates who reside in the New England region and can be in person on an as needed basis.

Requirements

  • Bachelor's degree in chemical engineering or a related field with 10+ years of relevant experience, or Master's degree with 8+ years of relevant experience
  • Experience with peptide or biologic drug substance late-phase/commercial manufacturing
  • Downstream operations experience such as chromatography purification, ultrafiltration or diafiltration, and lyophilization
  • Comprehensive understanding of cGMP principles and regulatory requirements, including process, equipment, and facility validation
  • Detail-oriented with strong problem-solving skills and ability to identify subtle trends in data
  • Excellent communication and teamwork skills
  • Demonstrated ability to lead technical discussions with external partners and influence cross-functional decisions without direct authority
  • Ability to communicate complex process risks clearly to technical and non-technical stakeholders
  • Ability to travel to domestic and international CMOs up to 20%

Benefits

  • Performance-based bonuses
  • Equity awards
  • Comprehensive benefits package

Company overview

Amylyx Pharmaceuticals is a clinical-stage pharmaceutical company based in Cambridge, Massachusetts, founded in 2013 by co-CEOs Josh Cohen and Justin Klee. The company specializes in developing novel therapies for neurodegenerative diseases with high unmet medical needs, with a particular focus on amyotrophic lateral sclerosis (ALS), Wolfram syndrome, and post-bariatric hypoglycemia. Amylyx's lead investigational therapy, AMX0035, received FDA approval for ALS treatment under the brand name RELYVRIO in September 2022. The company employs a rigorous scientific approach to target multiple pathological pathways in neurodegeneration, with additional pipeline candidates including avexitide for metabolic disorders and AMX0114, an antisense oligonucleotide targeting calpain-2 for ALS. With a team of 201-500 employees, Amylyx combines therapeutic development expertise with commercialization capabilities to address some of medicine's most challenging conditions.

Explore more jobs of your matchFind more biopharma roles with GetBioJob.